Enhertu® Followed Biologics License Application Accepted In The U.S. For Patients With Early-Stage Breast Cancer Prior To Surgery

Reuters
2025.10.01 11:15
Oct 1 (Reuters) - Daiichi Sankyo Co Ltd (4568.T) : * ENHERTU® FOLLOWED BY THP SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION ACCEPTED IN THE U.S. FOR PATIENTS WITH HIGH-RISK HER2 POSITIVE EARLY-STAGE BREAST CANCER PRIOR TO SURGERY * DAIICHI SANKYO CO LTD - FDA TARGET ACTION DATE FOR ENHERTU IS MAY 18, 2026 Source text: Further company coverage: (4568.T)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.